Edmond DE Rothschild Holding S.A. Buys 47,883 Shares of Zoetis Inc. $ZTS

Edmond DE Rothschild Holding S.A. raised its stake in Zoetis Inc. (NYSE:ZTS – Free Report) by 8.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 604,408 shares of the company’s stock after acquiring an additional 47,883 shares during the period. Edmond DE Rothschild Holding S.A. owned approximately 0.15% of Zoetis worth $42,206,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. BlackRock Inc. grew its holdings in shares of Zoetis by 10.8% during the 2nd quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock worth $2,833,453,000 after purchasing an additional 3,845,869 shares in the last quarter. State Street Corp raised its stake in Zoetis by 1.8% in the second quarter. State Street Corp now owns 19,667,723 shares of the company’s stock valued at $1,413,323,000 after purchasing an additional 343,322 shares in the last quarter. Deutsche Bank AG raised its stake in Zoetis by 5.8% in the second quarter. Deutsche Bank AG now owns 5,851,737 shares of the company’s stock valued at $420,506,000 after purchasing an additional 319,709 shares in the last quarter. Bank of America Corp DE lifted its position in Zoetis by 7.3% during the first quarter. Bank of America Corp DE now owns 4,831,652 shares of the company’s stock worth $571,150,000 after purchasing an additional 327,313 shares during the period. Finally, Van ECK Associates Corp lifted its position in Zoetis by 7.7% during the second quarter. Van ECK Associates Corp now owns 4,252,140 shares of the company’s stock worth $305,559,000 after purchasing an additional 303,395 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Key Stories Impacting Zoetis

These are some of the ZTS stories that stood out recently:

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. JPMorgan Chase & Co. decreased their target price on shares of Zoetis from $130.00 to $115.00 and set an “overweight” rating on the stock in a report on Friday, August 7th. TD Cowen dropped their target price on shares of Zoetis from $104.00 to $94.00 and set a “buy” rating for the company in a research report on Tuesday, August 25th. Weiss Ratings raised shares of Zoetis from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday, October 29th. Cantor Fitzgerald set a $94.00 price target on shares of Zoetis in a research report on Tuesday, August 25th. Finally, UBS Group increased their price target on shares of Zoetis from $80.00 to $85.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 27th. Eight research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $101.25.

View Our Latest Stock Report on Zoetis

Zoetis Trading Down 5.5%

ZTS opened at $80.85 on Friday. Zoetis Inc. has a fifty-two week low of $68.77 and a fifty-two week high of $132.49. The company has a debt-to-equity ratio of 2.51, a current ratio of 2.35 and a quick ratio of 1.40. The firm has a market capitalization of $32.85 billion, a price-to-earnings ratio of 13.75, a PEG ratio of 1.24 and a beta of 0.67. The company’s 50 day moving average price is $77.04 and its two-hundred day moving average price is $90.76.

Zoetis (NYSE:ZTS – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported $1.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.51 by $0.24. The firm had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 26.15% and a return on equity of 85.90%. The company’s revenue for the quarter was down 1.3% on a year-over-year basis. During the same quarter last year, the firm earned $1.70 earnings per share. As a group, research analysts predict that Zoetis Inc. will post 6.29 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, October 30th will be given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend is Friday, October 30th. Zoetis’s dividend payout ratio (DPR) is currently 36.05%.

Zoetis Profile

(Free Report)

Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish. The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.

See Also

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.